Selumetinib capsule formulation ( DrugBank: Selumetinib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
34. Neurofibromatosis
Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05309668 (ClinicalTrials.gov) | January 21, 2022 | 26/11/2021 | Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged =1 to <7 Years With NF1-related Symptomatic, Inoperable PN | A Phase I/II, Single-Arm, Open Label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged =1 to <7 Years With Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE) | Neurofibromatosis Type 1 | Drug: Selumetinib granule formulation;Drug: Selumetinib capsule formulation | AstraZeneca | Merck Sharp & Dohme LLC | Recruiting | 1 Year | 6 Years | All | 44 | Phase 1/Phase 2 | United States;Italy;Japan;Netherlands;Spain;Germany;Russian Federation |